Natural History Study of Synucleinopathies

Launched by NYU LANGONE HEALTH · Feb 26, 2013

Keywords

ClinConnect Summary

This clinical trial, called the Natural History Study of Synucleinopathies, is looking into a group of rare neurological disorders that affect movement and cognition due to the buildup of a protein called α-synuclein in the nervous system. These disorders can start with symptoms like slowness of movement or coordination difficulties, often becoming noticeable in people aged 50 or older. Some patients may first experience issues like dizziness when standing, constipation, or urinary problems before any brain-related symptoms appear. The goal of the study is to follow patients diagnosed with these conditions, as well as those showing early signs, to learn more about how these diseases progress over time and to identify potential biological markers that might predict which patients will develop more serious symptoms.

To participate in this study, individuals must be at least 18 years old, have symptoms related to orthostatic intolerance (like dizziness when standing), and be referred to one of the trial sites. However, people with certain conditions such as diabetes, heart failure, or those taking specific medications that could affect their symptoms may not be eligible. Participants can expect to attend follow-up visits where researchers will carefully monitor their symptoms and gather important information about the progression of these disorders. This study is essential for understanding the natural history of these diseases and could help improve future treatments.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Both male and female patients will be included
• • 2. Aged 18 or over
• • 3. Referred to any of the participating consortium sites with orthostatic intolerance, defined as symptoms of dizziness or lightheadedness in the standing position that disappear when supine.
• Exclusion Criteria:
• • 1. Diabetes according to the American Diabetes Association criteria
• • 2. Congestive heart failure
• • 3. Lupus or other collagen vascular disease
• • 4. Systemic illness thought to be responsible for the orthostatic intolerance
• • 5. Drug-induced orthostatic hypotension (i.e., the use of alpha-blockers, diuretics, tricyclic antidepressants or others thought by the investigator to play an important role in the patient's orthostatic hypotension)
• • 6. Isolated vasovagal syncope
• • 7. Inability to comply with the protocol, e.g. uncooperative attitude, inability to return for follow-up visits, and unlikelihood of completing the study.